Search Results for citation:"86 FR 6892"

Found 2 results
Skip to main content

Search Results: citation:"86 FR 6892"

  • Type:Notice
    Citation:86 FR 6892
    Reading Time:about 3 minutes

    The National Institutes of Health (NIH) is considering giving EpifiZa Inc., a company based in Canada, an exclusive license for some of its patented technologies. These inventions involve fusion proteins aimed at treating people with short stature due to genetic conditions. Public comments and license applications are being accepted until February 9, 2021. The license is intended to cover worldwide use, focusing on developing and selling treatments for growth-related disorders.

    Simple Explanation

    The government might let a company from Canada be the only one with special permission to use a new way of helping kids who don't grow tall enough, but this means they have to make sure it's fair to other companies too.

  • Type:Notice
    Citation:86 FR 6892
    Reading Time:about 2 minutes

    The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.

    Simple Explanation

    The National Cancer Institute is thinking about letting Ziopharm Oncology use special recipes they came up with to make medicine that can help fight cancer. They want to hear from people who have thoughts or ideas about this by February 9, 2021.